Over 70m votes turned out in July for #AVCT’s 2025 AGM.
This notion @avacta’s predominantly retail register may be unable to mobilise 25% (against any bid which may be considered derisory) is misguided.
The same base refused to accept a solution to the CLN could not be found.
TVR5 formed with one objective: to support change to #AVCT’s board.
Because of those changes @avacta has transformed how its commercial acumen is perceived by the market.
As a group, we look forward to the independent validation which will follow 51 months of clinical data.
As a shareholder base representing 9.19% of #AVCT’s TVR, we are delighted to see a board member finally grappling with the thorny issues and finding solutions.
Richard has @TVR5AVCT’s full support.
#Hughes4Chair
You’re reminded any solution to #AVCT’s CLN was previously dismissed as unobtainable because obstructive noteholders made it impossible.
Turns out if you stick a proven deal-maker around the table you will find a solution.
#Hughes4Chair
Today’s deferment of the loan note protects shareholders and restores value; allowing #AVCT to focus on the advancement of preCISION.
TVR5 would like to see Richard Hughes move into an executive position. His track record of protecting shareholders is clear.
#Hughes4Chair
What an utterly brilliant way to present the 2023 sewage dumping data. Just enter you postcode. 👋👋👋
Deserving of an award me thinks.
https://t.co/WC7H2ZoQSx